New RAS Inhibitor Daraxonrasib Beats Chemo in Metastatic Pancreatic Cancer
Phase 3 trial shows daraxonrasib significantly extends survival in previously treated pancreatic cancer patients.
Summary
Pancreatic ductal adenocarcinoma is one of the deadliest cancers, with very few effective treatment options after first-line chemotherapy fails. The RASolute 302 phase 3 clinical trial tested daraxonrasib, a next-generation RAS(ON) inhibitor, against standard chemotherapy in patients with previously treated metastatic disease. Results showed daraxonrasib produced significantly longer overall survival and progression-free survival compared to chemotherapy. RAS mutations drive a large proportion of pancreatic cancers and have historically been considered nearly undruggable targets. This trial represents a meaningful advance in targeting oncogenic RAS signaling directly, offering a new treatment pathway for a cancer type with notoriously poor prognosis. The findings have implications for how oncologists approach second-line treatment in this setting.
Detailed Summary
Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses of any solid tumor, with an overall five-year survival rate around 12–13% across all stages. Metastatic PDAC treated with second-line chemotherapy typically offers median survival measured in months, so any therapy that meaningfully extends life in this setting is a significant clinical advance.
The RASolute 302 trial is a phase 3 randomized study evaluating daraxonrasib, described as a RAS(ON) inhibitor, in patients with previously treated metastatic PDAC. RAS mutations — particularly KRAS — are present in the large majority of pancreatic cancers and act as master drivers of tumor proliferation and survival. Daraxonrasib is designed to inhibit the active, GTP-bound form of RAS protein, though the specific mutation spectrum covered is not detailed in the abstract.
The trial demonstrated that daraxonrasib produced significantly longer overall survival and progression-free survival compared to standard chemotherapy. Both endpoints reaching significance in a notoriously treatment-resistant cancer type marks a substantial step forward and suggests that direct RAS inhibition is a clinically viable strategy in this setting.
Caveats include the limited abstract-only data available, meaning specific hazard ratios, median survival figures, and safety profiles are not yet fully evaluable here. The trial enrolled previously treated patients, so applicability to first-line settings remains unknown. Full peer-reviewed data publication at NEJM.org will be essential for comprehensive clinical interpretation.
Key Findings
- Daraxonrasib significantly improved overall survival vs chemotherapy in previously treated metastatic PDAC.
- Progression-free survival was also significantly longer with daraxonrasib than with standard chemotherapy.
- Daraxonrasib is described as a RAS(ON) inhibitor, targeting the active GTP-bound form of oncogenic RAS protein.
- RAS mutations are present in the large majority of pancreatic cancers, making the pathway a key therapeutic target.
- RASolute 302 is a phase 3 randomized trial showing benefit from direct RAS pathway inhibition in metastatic PDAC.
Methodology
RASolute 302 is a phase 3 randomized controlled trial comparing daraxonrasib to chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma. Primary endpoints included overall survival and progression-free survival. Full methodology details, randomization, and patient characteristics are available in the complete NEJM publication.
Study Limitations
This summary is based on the abstract only, as the full trial paper is not open access; specific survival medians, hazard ratios, and adverse event rates are unavailable here. The trial enrolled previously treated patients, limiting generalizability to first-line or earlier-stage disease. Independent validation and longer follow-up data will be needed to confirm durability of survival benefit.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: